Workshop on integration site analysis during long term follow-up for gene therapies with integrating viral vectors (from Catapult's regulatory round-up for November 2024)
The FDA’s CBER Office of Therapeutic Products (OTP) hosted a virtual scientific public workshop on 14th November 2024 to discuss the clinical use of integration site analysis (ISA) during long term follow-up following administration of gene therapies with integrating viral vectors. In this workshop, FDA convened a panel of external experts to discuss the risk of insertional mutagenesis and best practices for ISA method design, data analysis, and clinical interpretation. The video recording o...
Publication Details
- Journal
- Industrias Culturais (Universidade de Coimbra)
- Published
- 2025-02-12
- DOI
- https://doi.org/10.58079/13axq
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00